drugset / Trial / NCT01524887
Phase 3 IGIV, 10% in Alzheimer´s Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to provide evidence of efficacy and safety to support the development of IGIV, 10% as a treatment option for patients with mild to moderate Alzheimer´s Disease.
Timeline
- Start
- 2012-01-23
- Primary completion
- 2013-07-16
- Completion
- 2013-07-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 0.2 g/kg | Intravenous |
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 0.4 g/kg | Intravenous |